Literature DB >> 21784819

Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.

Roberta Camilla1, Hitoshi Suzuki, Valentina Daprà, Elisa Loiacono, Licia Peruzzi, Alessandro Amore, Gian Marco Ghiggeri, Gianna Mazzucco, Francesco Scolari, Ali G Gharavi, Gerald B Appel, Stéphan Troyanov, Jan Novak, Bruce A Julian, Rosanna Coppo.   

Abstract

BACKGROUND AND OBJECTIVES: We assessed the activation of the oxidative stress pathway in patients with IgA nephropathy (IgAN), while evaluating the classic marker of the disease (galactose-deficient serum IgA1). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sera from 292 patients and 69 healthy controls from Italy and the United States were assayed for advanced oxidation protein products (AOPPs), free sulfhydryl groups on albumin (SH-Alb), and IgA1 with galactose-deficient hinge-region O-glycans (Gd-IgA1). Gd-IgA1 was detected by binding to Helix aspersa agglutinin (HAA) and expressed as total Gd-IgA1 or as degree of galactose deficiency relative to a standard Gd-IgA1 myeloma protein (%HAA).
RESULTS: Sera from IgAN patients showed higher levels of Gd-IgA1, %HAA, and AOPPs, but lower levels of SH-Alb in comparison to that from healthy controls. Serum levels of AOPPs significantly correlated with serum Gd-IgA1 and %HAA. The relationship between these biomarkers and clinical features at sampling and during follow-up was assessed in 62 patients with long-term follow-up. AOPPs and %HAA correlated with proteinuria at sampling and independently associated with subsequent proteinuria. Levels of AOPPs correlated with rate of decline in renal function after sampling. The combination of a high level of AOPPs and a high level of %HAA associated with decline in estimated GFR.
CONCLUSIONS: Serum levels of aberrantly glycosylated IgA1 are elevated and oxidative stress pathways are activated in patients with IgAN; the intensity of the stress correlated with expression and progression of the disease. We speculate that oxidative stress may modulate the nephrotoxicity of aberrantly glycosylated IgA1 in IgAN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784819      PMCID: PMC3156425          DOI: 10.2215/CJN.11571210

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  39 in total

1.  Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.

Authors:  Ali G Gharavi; Zina Moldoveanu; Robert J Wyatt; Catherine V Barker; Susan Y Woodford; Richard P Lifton; Jiri Mestecky; Jan Novak; Bruce A Julian
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

Review 2.  Estimating and measuring glomerular filtration rate in children.

Authors:  Dana F Work; George J Schwartz
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-05       Impact factor: 2.894

3.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

4.  Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients.

Authors:  Katsumi Mera; Makoto Anraku; Kenichiro Kitamura; Keisuke Nakajou; Toru Maruyama; Kimio Tomita; Masaki Otagiri
Journal:  Hypertens Res       Date:  2005-12       Impact factor: 3.872

Review 5.  Oxidants in chronic kidney disease.

Authors:  Sudhir V Shah; Radhakrishna Baliga; Mohan Rajapurkar; Vivian A Fonseca
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

6.  Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation.

Authors:  Rosanna Coppo; Alessandro Amore; Monica Chiesa; Federica Lombardo; Paola Cirina; Simeone Andrulli; Patrizia Passerini; Giovanni Conti; Licia Peruzzi; Roberta Giraudi; Maria Messina; Giuseppe Segoloni; Claudio Ponticelli
Journal:  Clin Transplant       Date:  2007 Nov-Dec       Impact factor: 2.863

7.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

8.  IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.

Authors:  Hitoshi Suzuki; Zina Moldoveanu; Stacy Hall; Rhubell Brown; Huong L Vu; Lea Novak; Bruce A Julian; Milan Tomana; Robert J Wyatt; Jeffrey C Edberg; Graciela S Alarcón; Robert P Kimberly; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 9.  Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.

Authors:  J Mestecky; M Tomana; Z Moldoveanu; B A Julian; H Suzuki; K Matousovic; M B Renfrow; L Novak; R J Wyatt; J Novak
Journal:  Kidney Blood Press Res       Date:  2008-01-08       Impact factor: 2.687

10.  Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.

Authors:  Z Moldoveanu; R J Wyatt; J Y Lee; M Tomana; B A Julian; J Mestecky; W-Q Huang; S R Anreddy; S Hall; M C Hastings; K K Lau; W J Cook; J Novak
Journal:  Kidney Int       Date:  2007-03-07       Impact factor: 10.612

View more
  45 in total

1.  Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway.

Authors:  Wei Cao; Jie Xu; Zhan Mei Zhou; Guo Bao Wang; Fan Fan Hou; Jing Nie
Journal:  Antioxid Redox Signal       Date:  2012-07-30       Impact factor: 8.401

Review 2.  IgA nephropathy and oxidative stress: news on clinically evaluated biomarkers hits the stage.

Authors:  Cheng Zhu; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-06-10       Impact factor: 2.370

Review 3.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

4.  Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Authors:  Luca Vergano; Elisa Loiacono; Roberto Albera; Rosanna Coppo; Roberta Camilla; Licia Peruzzi; Alessandro Amore; Maria Elena Donadio; Federica Chiale; Alberto Boido; Filippo Mariano; Gianna Mazzucco; Sara Ravera; Giovanni Cancarini; Riccardo Magistroni; Giulietta Beltrame; Cristiana Rollino; Piero Stratta; Marco Quaglia; Roberto Bergia; Raffaella Cravero; Stefano Cusinato; Luisa Benozzi; Silvana Savoldi; Carola Licata
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

Review 5.  The genetics and immunobiology of IgA nephropathy.

Authors:  Krzysztof Kiryluk; Jan Novak
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 6.  Biomarkers and targeted new therapies for IgA nephropathy.

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2016-06-20       Impact factor: 3.714

Review 7.  Glycosylation of IgA1 and pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Jiri Mestecky; Matthew B Renfrow
Journal:  Semin Immunopathol       Date:  2012-03-21       Impact factor: 9.623

8.  Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-01-06

9.  Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation.

Authors:  Yanhong Wang; Jihua Tian; Haixiu Guo; Yang Mi; Ruijing Zhang; Rongshan Li
Journal:  Clin Exp Med       Date:  2015-04-28       Impact factor: 3.984

10.  Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.

Authors:  Francois Berthoux; Hitoshi Suzuki; Lise Thibaudin; Hiroyuki Yanagawa; Nicolas Maillard; Christophe Mariat; Yasuhiko Tomino; Bruce A Julian; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.